2023 World Conference on Lung Cancer (Posters)-P2.09. Real World Analysis Afatinib as a First Line Treatment Patients with Advanced Stage Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations

P2.09. Real World Analysis Afatinib as a First Line Treatment Patients with Advanced Stage Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the effectiveness of the drug Afatinib as a first-line treatment for patients with advanced stage non-small cell lung cancer (NSCLC) who have uncommon EGFR mutations. The study analyzed the data of 92 patients with locally advanced and metastatic NSCLC who received Afatinib as their initial therapy. The patients were followed and evaluated regularly, and the objective response rate (ORR), time to treatment failure (TTF), and adverse events were assessed.<br /><br />The results showed that the median age of the patients was 63 years old, with 26.1% of them having brain metastases. The most common EGFR mutation was G719X, which accounted for 53.3% of the cases. The usual starting dose of Afatinib was 30mg per day, and 20.7% of patients required a dose reduction due to toxicity.<br /><br />The median follow-up period was 22.7 months. The ORR was 75%, with 15.2% of patients achieving a complete response. The overall median TTF was 13.8 months, and 23.6% of patients continued treatment at 2 years. Patients with the G719X mutation had a significantly longer median TTF of 19.3 months compared to those with other mutations.<br /><br />Patients with compound EGFR mutations G719X and S768I also had a longer median TTF of 23.2 months compared to those with other mutations. There was no statistically significant difference in TTF between patients receiving different starting doses. However, patients who tolerated a dose of 20 mg or 30 mg achieved a longer median TTF compared to those on a dose of 40 mg.<br /><br />The most common adverse events were rash and diarrhea, but they were mainly graded as mild or moderate. In conclusion, Afatinib was found to be an effective treatment option for patients with advanced NSCLC and uncommon EGFR mutations, particularly those with the G719X mutation and lower doses of Afatinib.

Asset Subtitle

Luan Pham

Meta Tag

Speaker Luan Pham

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Afatinib

first-line treatment

advanced stage non-small cell lung cancer

NSCLC

uncommon EGFR mutations

objective response rate

time to treatment failure

adverse events

G719X mutation

dose reduction